NASDAQ:APTO Aptose Biosciences (APTO) Stock Price, News & Analysis → Jeff Bezos & 48 Members of Congress Are Buying ONE Sector… (From InvestorPlace) (Ad) Free APTO Stock Alerts $0.89 -0.04 (-4.30%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$0.85▼$1.0050-Day Range$0.88▼$1.4752-Week Range$0.85▼$6.00Volume133,314 shsAverage Volume71,858 shsMarket Capitalization$16.10 millionP/E RatioN/ADividend YieldN/APrice Target$14.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Aptose Biosciences alerts: Email Address Aptose Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,566.7% Upside$14.83 Price TargetShort InterestHealthy0.53% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.41Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.67) to ($3.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.15 out of 5 starsMedical Sector769th out of 914 stocksBiological Products, Except Diagnostic Industry126th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingAptose Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAptose Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Aptose Biosciences' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.53% of the float of Aptose Biosciences has been sold short.Short Interest Ratio / Days to CoverAptose Biosciences has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aptose Biosciences has recently increased by 13.07%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAptose Biosciences does not currently pay a dividend.Dividend GrowthAptose Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APTO. Previous Next 2.4 News and Social Media Coverage News SentimentAptose Biosciences has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Aptose Biosciences this week, compared to 1 article on an average week.Search Interest4 people have searched for APTO on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Aptose Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aptose Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of Aptose Biosciences is held by insiders.Percentage Held by InstitutionsOnly 26.62% of the stock of Aptose Biosciences is held by institutions.Read more about Aptose Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aptose Biosciences are expected to decrease in the coming year, from ($2.67) to ($3.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aptose Biosciences is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aptose Biosciences is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Aptose Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing demand from Central Banks and billionaires to EXPLODE! The elites are buying up gold like nothing we've seen before… Click here now to download the free Precious Metals Buying Guide. About Aptose Biosciences Stock (NASDAQ:APTO)Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Read More APTO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APTO Stock News HeadlinesJune 15 at 5:28 AM | americanbankingnews.comAptose Biosciences (NASDAQ:APTO) Coverage Initiated by Analysts at StockNews.comJune 14 at 11:48 AM | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Aptose Biosciences (NASDAQ:APTO)June 14 at 7:30 AM | globenewswire.comAptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid CongressJune 14 at 1:03 AM | americanbankingnews.comQ2 2024 Earnings Estimate for Aptose Biosciences Inc. Issued By HC Wainwright (NASDAQ:APTO)June 9, 2024 | americanbankingnews.comAnalysts Set Aptose Biosciences Inc. (NASDAQ:APTO) Price Target at $17.50June 6, 2024 | americanbankingnews.comStockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO)June 3, 2024 | globenewswire.comAptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 31, 2024 | globenewswire.comAptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 14, 2024 | globenewswire.comAptose Reports Results for the First Quarter 2024May 6, 2024 | globenewswire.comAptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024March 29, 2024 | investing.comAptose Biosciences target cut, maintains buy rating on new drug developmentMarch 28, 2024 | finanznachrichten.deAptose Biosciences, Inc.: Aptose Reports Results for the Fourth Quarter and Full Year 2023March 27, 2024 | finance.yahoo.comAptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | msn.comEdgewood secures $20m in Series A for clinical development of cancer therapyMarch 27, 2024 | benzinga.comRecap: Aptose Biosciences Q4 EarningsMarch 26, 2024 | globenewswire.comAptose Reports Results for the Fourth Quarter and Full Year 2023March 18, 2024 | globenewswire.comAptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024January 29, 2024 | finance.yahoo.comThis Aptose Biosciences Insider Increased Their Holding In The Last YearJanuary 26, 2024 | marketwatch.comAptose Biosciences Shares Drop 11% After Private, Public OfferingsJanuary 26, 2024 | markets.businessinsider.comAptose Prices Offering Of About 4.91 Mln Shares At $1.71/Share, $4 Private Placement With HanmiJanuary 26, 2024 | finance.yahoo.comAptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi PharmaceuticalJanuary 26, 2024 | investorplace.comWhy Is Aptose Biosciences (APTO) Stock Down Today?December 21, 2023 | benzinga.comAptose Biosciences Stock (NASDAQ:APTO), Guidance and ForecastDecember 5, 2023 | morningstar.comAptose Biosciences Inc APTODecember 4, 2023 | msn.comAptose Biosciences files to sell ordinary shares, warrantsSee More Headlines Receive APTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/16/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:APTO CUSIPN/A CIK882361 Webwww.aptose.com Phone858-926-2730Fax905-234-2120Employees31Year FoundedN/APrice Target and Rating Average Stock Price Target$14.83 High Stock Price Target$38.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,566.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($6.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,003.74% Return on Assets-257.64% Debt Debt-to-Equity RatioN/A Current Ratio0.97 Quick Ratio0.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.19) per share Price / Book-4.68Miscellaneous Outstanding Shares18,090,000Free Float17,256,000Market Cap$16.10 million OptionableNo Data Beta1.39 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. William G. Rice Ph.D. (Age 59)Chairman, Pres & CEO Mr. Gregory K. Chow CPA (Age 45)MBA, BA, Sr. VP, CFO & Principal Accounting Officer Mr. Ernest Kitt B.S.M.S, VP of Devel. & Technical OperationsDr. Stephen B. Howell (Age 73)Chief Medical Officer Mr. Peter MurrayDirector of Clinical Devel.Key CompetitorsAVROBIONASDAQ:AVROTurnstone BiologicsNASDAQ:TSBXAtara BiotherapeuticsNASDAQ:ATRACidara TherapeuticsNASDAQ:CDTXDyadic InternationalNASDAQ:DYAIView All CompetitorsInsidersBernd R SeizingerBought 17,000 shares on 9/22/2023Total: $53,380.00 ($3.14/share)View All Insider Transactions APTO Stock Analysis - Frequently Asked Questions Should I buy or sell Aptose Biosciences stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APTO shares. View APTO analyst ratings or view top-rated stocks. What is Aptose Biosciences' stock price target for 2024? 6 Wall Street research analysts have issued 12 month price objectives for Aptose Biosciences' shares. Their APTO share price targets range from $5.00 to $38.00. On average, they anticipate the company's stock price to reach $14.83 in the next year. This suggests a possible upside of 1,566.7% from the stock's current price. View analysts price targets for APTO or view top-rated stocks among Wall Street analysts. How have APTO shares performed in 2024? Aptose Biosciences' stock was trading at $2.54 at the start of the year. Since then, APTO stock has decreased by 65.0% and is now trading at $0.89. View the best growth stocks for 2024 here. Are investors shorting Aptose Biosciences? Aptose Biosciences saw a increase in short interest in May. As of May 31st, there was short interest totaling 77,000 shares, an increase of 13.1% from the May 15th total of 68,100 shares. Based on an average daily trading volume, of 66,200 shares, the short-interest ratio is presently 1.2 days. Approximately 0.5% of the shares of the stock are sold short. View Aptose Biosciences' Short Interest. When is Aptose Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our APTO earnings forecast. How were Aptose Biosciences' earnings last quarter? Aptose Biosciences Inc. (NASDAQ:APTO) announced its quarterly earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.73) earnings per share for the quarter, topping analysts' consensus estimates of ($0.82) by $0.09. When did Aptose Biosciences' stock split? Shares of Aptose Biosciences reverse split on the morning of Tuesday, June 6th 2023. The 1-15 reverse split was announced on Tuesday, June 6th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is William G. Rice, Ph.D.'s approval rating as Aptose Biosciences' CEO? 8 employees have rated Aptose Biosciences Chief Executive Officer William G. Rice, Ph.D. on Glassdoor.com. William G. Rice, Ph.D. has an approval rating of 34% among the company's employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 52.0% of employees surveyed would recommend working at Aptose Biosciences to a friend. What other stocks do shareholders of Aptose Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), Cisco Systems (CSCO), Micron Technology (MU) and SCYNEXIS (SCYX). Who are Aptose Biosciences' major shareholders? Aptose Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bernd R Seizinger, Denis R Burger, Donald R Jr Wilson, Erich Platzer, Rafael Bejar, Warren Whitehead and William G Rice. View institutional ownership trends. How do I buy shares of Aptose Biosciences? Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:APTO) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptose Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.